Laboratory Equipment and Instruments

The lab is expected to open in April 2020 and will increase the company’s capacity for diagnostic testing of rare genetic diseases along with its COVID-19 capabilities.

The strategic alliance provides an integrated product offering around drug discovery and development.

The company has developed mathematical algorithms that generate simple cell-count data from a few days of culture.

The new NAB Nanosep device provides increased binding capacity.

The company has launched new high volume eight- and 12-channel pipettes, offering a capacity of 1250 µL per channel.

The transgenic mouse R&D platform will support the discovery of fully-human monoclonal antibodies.

The acquisition will expand Nexelis’ immunology testing expertise.

Eurofins DiscoverX partners with VelaLabs to enable VelaLabs to perform highly reproducible potency lot release assays under GLP/GMP conditions.

Data management is crucial in bio/pharmaceutical laboratory settings from discovery steps through clinical studies and varies based on the development phase.

The partners will collaborate on developing scale-up chip-based technology to enable commercial-scale production of a third-generation DNA synthesis platform.

The license gives Daiichi Sankyo access to ERS Genomics’ genome-editing technology for internal R&D initiatives.

The company’s new Milliflex Oasis System provides enhanced result reliability, increased productivity, and advanced traceability.

Otsuka will use PhoreMost’s phenotypic screening platform to identify new targets for drug development, with a focus on gene therapy.

The Ireland-based company can now offer complete elemental impurities testing services.

The new GMP conditioning product offering is designed to support clinical phase and commercialization stages of cell and gene therapy production.

GE Healthcare Life Sciences and Advanced Solutions Life Sciences (ASLS) are partnering on 3D-printing of tissues that can be used for discovery and cytotoxicity testing.

The company showcased its compact robotic nest filling machine at CPhI Worldwide 2019 on Nov.–7 in Frankfurt, Germany.

The company is expanding its bioanalytical capacity and capabilities to support biologic drug development, cell and gene therapy development, and biomarker analysis.

Clear Advantage is a product line of multichannel reagent reservoirs to be used for creating a next-gen sequencing library

The companies will present the SV model a semi-automatic machine for the inspection of liquid, lyophilized, or powder products in ampoules, vials, cartridges, and pre-filled syringes.

The new location is one of the world’s first digital facilities to use intensified, continuous biologics production technology.

The new services provide rapid production of antibody drug conjugates (ADCs) for best candidate selection.

The companies agreed to a multi-year research and development collaboration that will focus on AI empowerment and exploration.

PPD is expanding its bioanalytical lab in Richmond, VA, to enhance its immunochemistry, biomarker, and chromatography services.

A new educational platform by Quality Executive Partners offers on-demand digital courses with technical content, virtual reality, and real-time coaching with an initial focus on sterile product manufacturing and microbiology.

Cellink’s BIO X6, a six-printhead bioprinting platform, offers the capability to combine more materials, cells, and tools to enhance research applications across the bioprinting field.

Cell DIVE is a new cell imaging technology from GE Healthcare that allows for more precise biomarker analysis.

The new microscope gives fast, deep, and clear images for live observation over long periods and allows scientists to study a larger range of applications.

The device can produce up to 130,000 tablets per hour and completes design of experiment and research studies with little material and multiple tooling formats.

A new defined coated cell cultureware by denovoMATRIX allow for the serum-free expansion of mesenchymal stem cells.